Data_Sheet_1_Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogen.pdf (368.88 kB)
Download file

Data_Sheet_1_Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.pdf

Download (368.88 kB)
dataset
posted on 18.12.2019, 04:12 by Thomas Mika, Katharina Strate, Swetlana Ladigan, Clemens Aigner, Uwe Schlegel, Iris Tischoff, Sabine Tischer-Zimmermann, Britta Eiz-Vesper, Britta Maecker-Kolhoff, Roland Schroers

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory PTLD are scarce. Today, there is no consensus how to treat rituximab-refractory PTLD, especially in highly aggressive disease. Here, we describe successful management of refractory EBV-associated PTLD, specifically DLBCL, with combined brentuximab vedotin and third-party EBV-specific T-cells in a multidisciplinary treatment approach.

History